Company registration number 04383577 (England and Wales)
MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
PAGES FOR FILING WITH REGISTRAR
MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
BALANCE SHEET
AS AT
31 MARCH 2024
31 March 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
592
1,050
Investments
4
1,048
1,048
1,640
2,098
Current assets
Stocks
237,161
228,991
Debtors
5
211,072
224,299
Cash at bank and in hand
2,616
224
450,849
453,514
Creditors: amounts falling due within one year
6
(261,982)
(236,715)
Net current assets
188,867
216,799
Total assets less current liabilities
190,507
218,897
Creditors: amounts falling due after more than one year
7
(201,614)
(216,284)
Net (liabilities)/assets
(11,107)
2,613
Capital and reserves
Called up share capital
8
849
849
Share premium account
689,628
689,628
Profit and loss reserves
(701,584)
(687,864)
Total equity
(11,107)
2,613

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 MARCH 2024
31 March 2024
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 5 March 2025
Prof. Martin Levermore MBE DL Chartered MCISI
Director
Company Registration No. 04383577
MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024
- 3 -
1
Accounting policies
Company information

Medical Devices Technology International Limited is a private company limited by shares incorporated in England and Wales. The registered office is Kace Building, Victoria Passage, Wolverhampton, WV1 4LG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The truecompany meets its day to day working capital requirements through small short term loans from shareholders where necessary.

 

During the year the company has continued to re-brand which has involved a high cash outflow. This is a short term cash flow issue which given the increase of trade through Amazon will be resolved in the near future and the company will see an increase in trade. On this basis, the director consider it appropriate to prepare the financial statements on the going concern basis.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
20% straight line
Fixtures, fittings & equipment
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
1
Accounting policies
(Continued)
- 5 -
1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Trade debtors, loans and other receivables that have fixed or determinable payments that are not quoted in an active market are classified as 'loans and receivables'. Loans and receivables are measured at amortised cost using the effective interest method, less any impairment.

 

Interest is recognised by applying the effective interest rate, except for short-term receivables when the recognition of interest would be immaterial. The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating the interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the debt instrument to the net carrying amount on initial recognition.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
1
Accounting policies
(Continued)
- 6 -
1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

 

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
3
3
MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
- 7 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2023 and 31 March 2024
52,767
Depreciation and impairment
At 1 April 2023
51,717
Depreciation charged in the year
458
At 31 March 2024
52,175
Carrying amount
At 31 March 2024
592
At 31 March 2023
1,050

At the year end the company has paid £70,473.51 towards moulding machinery with a cost price of £119,965. The ownership of these assets will transfer once the cost of the assets have been paid in full.

4
Fixed asset investments
2024
2023
£
£
Other investments other than loans
1,048
1,048
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
25,128
40,903
Other debtors
36,143
33,595
61,271
74,498
2024
2023
Amounts falling due after more than one year:
£
£
Deferred tax asset
149,801
149,801
Total debtors
211,072
224,299
MEDICAL DEVICES TECHNOLOGY INTERNATIONAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024
- 8 -
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
9,538
38,220
Taxation and social security
80,052
70,881
Other creditors
172,392
127,614
261,982
236,715
7
Creditors: amounts falling due after more than one year
2024
2023
£
£
Other creditors
201,614
216,284
8
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of 10p each
8,494
8,494
849
849
2024-03-312023-04-01falsefalsefalse05 March 2025CCH SoftwareCCH Accounts Production 2024.310No description of principal activityProf. Martin Levermore MBE DL Chartered MCISIProf. Martin Levermore MBE DL Chartered MCISI043835772023-04-012024-03-31043835772024-03-31043835772023-03-3104383577core:OtherPropertyPlantEquipment2024-03-3104383577core:OtherPropertyPlantEquipment2023-03-3104383577core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3104383577core:CurrentFinancialInstrumentscore:WithinOneYear2023-03-3104383577core:Non-currentFinancialInstrumentscore:AfterOneYear2024-03-3104383577core:Non-currentFinancialInstrumentscore:AfterOneYear2023-03-3104383577core:CurrentFinancialInstruments2024-03-3104383577core:CurrentFinancialInstruments2023-03-3104383577core:ShareCapital2024-03-3104383577core:ShareCapital2023-03-3104383577core:SharePremium2024-03-3104383577core:SharePremium2023-03-3104383577core:RetainedEarningsAccumulatedLosses2024-03-3104383577core:RetainedEarningsAccumulatedLosses2023-03-3104383577bus:CompanySecretaryDirector12023-04-012024-03-3104383577core:PlantMachinery2023-04-012024-03-3104383577core:FurnitureFittings2023-04-012024-03-31043835772022-04-012023-03-3104383577core:OtherPropertyPlantEquipment2023-03-3104383577core:OtherPropertyPlantEquipment2023-04-012024-03-3104383577core:WithinOneYear2024-03-3104383577core:WithinOneYear2023-03-3104383577core:AfterOneYear2024-03-3104383577core:AfterOneYear2023-03-3104383577core:Non-currentFinancialInstruments2024-03-3104383577core:Non-currentFinancialInstruments2023-03-3104383577bus:PrivateLimitedCompanyLtd2023-04-012024-03-3104383577bus:FRS1022023-04-012024-03-3104383577bus:AuditExemptWithAccountantsReport2023-04-012024-03-3104383577bus:Director12023-04-012024-03-3104383577bus:CompanySecretary12023-04-012024-03-3104383577bus:SmallCompaniesRegimeForAccounts2023-04-012024-03-3104383577bus:FullAccounts2023-04-012024-03-31xbrli:purexbrli:sharesiso4217:GBP